Omar El-Charif, MD
Clinical FellowDownloadHi-Res Photo
About
Copy Link
Titles
Clinical Fellow
Biography
Omar El-Charif is a resident physician in the Department of Internal Medicine at Yale New Haven within the Physician-Scientist Training Program. Dr. El-Charif's research interests involve using high-throughput multi-omic data to develop predictive signatures that personalize diagnostic, prognostic, and therapeutic decisions. His expertise includes Genome-Wide Association Studies (GWAS), transcriptomics, functional SNP analysis, and eQTL-mapping. He is also passionate about teaching-learning and medical education. Aside from work, he loves to listen to, play, and compose music, and pursue the best of each dish in town.
Last Updated on April 27, 2025.
Departments & Organizations
Education & Training
- MD
- University of Rochester School of Medicine (2022)
- BA
- The University of Chicago (2016)
Research
Copy Link
Research at a Glance
Publications Timeline
A big-picture view of Omar El-Charif's research output by year.
7Publications
34Citations
Publications
2021
Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
Trendowski MR, Baedke JL, Sapkota Y, Travis LB, Zhang X, El Charif O, Wheeler HE, Leisenring WM, Robison LL, Hudson MM, Morton LM, Oeffinger KC, Howell RM, Armstrong GT, Bhatia S, Dolan ME. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer 2021, 127: 4091-4102. PMID: 34286861, PMCID: PMC8516694, DOI: 10.1002/cncr.33775.Peer-Reviewed Original Research
2020
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research 2020, 26: 6550-6558. PMID: 32998964, PMCID: PMC7744329, DOI: 10.1158/1078-0432.ccr-20-2682.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinCancer SurvivorsCisplatinEtoposideFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansIfosfamideMaleMiddle AgedNeoplasmsNeurotoxicity SyndromesPolymorphism, Single NucleotidePrognosisRisk FactorsSurvival RateVinblastineConceptsCumulative cisplatin doseCisplatin doseSevere neurotoxicityCancer survivorsRisk factorsAdult-onset cancer survivorsLifestyle/behavioral factorsCisplatin-induced neurotoxicityDizziness/vertigoNeuro-otological symptomsPeripheral sensory neuropathyPoor overall healthPeripheral motor neuropathyImportant risk factorTesticular cancer survivorsQuality of lifeSerum platinum levelsDose adjustmentMotor neuropathyRaynaud's phenomenonSensory neuropathyNeurotoxicity riskPsychotropic medicationsClinical examinationMedical history
2019
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy
Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clinical Cancer Research 2019, 25: 5913-5924. PMID: 31296530, PMCID: PMC6774840, DOI: 10.1158/1078-0432.ccr-19-0113.Peer-Reviewed Original ResearchCitationsAltmetricAdverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB, _ _. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2019, 17: 459-468. PMID: 31085753, PMCID: PMC6712564, DOI: 10.6004/jnccn.2018.7109.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTesticular cancer survivorsPlatinum-based chemotherapyRisk factorsErectile dysfunctionCancer survivorsFirst-line platinum-based chemotherapyHealth outcomesMultivariable binary logistic regression analysisCisplatin-based chemotherapy regimenCardiovascular disease risk factorsVigorous-intensity physical activityPrevalence of hypogonadismTestosterone replacement therapyDisease risk factorsSerum testosterone levelsBody mass indexBinary logistic regression analysisYounger median ageAdverse health outcomesLogistic regression analysisYears of ageAnxiety/depressionGenetic risk factorsChemotherapy regimenSymptomatic patientsGenetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.
Trendowski MR, El Charif O, Dinh PC, Travis LB, Dolan ME. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 1147-1155. PMID: 30305294, PMCID: PMC6377815, DOI: 10.1158/1078-0432.CCR-18-2244.Peer-Reviewed Original Research
2018
Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.
Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC, Sesso HD, Einhorn LH, Fossa SD, Travis LB. Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 257-265. PMID: 29523664, PMCID: PMC6345519, DOI: 10.6004/jnccn.2017.7046.Peer-Reviewed Original Research
2017
Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.
Mapes B, El Charif O, Al-Sawwaf S, Dolan ME. Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 4010-4019. PMID: 28442506, PMCID: PMC5540779, DOI: 10.1158/1078-0432.CCR-17-0429.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Copy Link
Honors
honor Distinction in Medical Education
06/08/2022National AwardUniversity of Rochester School of Medicine and DentistryDetailsUnited Stateshonor Doran J. Stephens Prize
05/12/2022National AwardUniversity of Rochester School of Medicine and DentistryDetailsUnited Stateshonor Alpha Omega Alpha
05/10/2022National AwardDetailsUnited Stateshonor Gold Humanism Award
05/10/2022National AwardDetailsUnited States
News
Copy Link
News
Get In Touch
Copy Link